Potential pulmonary fibrosis therapy CAL101 fares well in study

Potential pulmonary fibrosis therapy CAL101 fares well in study

CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by Calluna Pharma, its developer. “These results are an important step forward in the development of our lead asset, CAL101,…

Now you know: Updates from my journey living with IPF

How is it already November? Here in the U.S., today is Election Day, so get out and vote if you haven’t already done so. I wanted to take the opportunity this week to update you on topics I’ve discussed in several recent columns. My bronchoscopy Diagnosed with idiopathic…

Keeping track of meds is part of my post-transplant plan

What medications do you take regularly, and what are they for? Do you know the possible side effects? When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I didn’t take many medications. I took a blood pressure medication, an over-the-counter (OTC) allergy pill, and…

Pro-fibrotic immune cell detected in lungs of long COVID-19 patients

Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent breathing problems after recovering from COVID-19. The cells’ abundance correlated with the severity of fibrosis, or tissue scarring, as detected by CT scans. “The underlying cells and molecules that contribute…

IPF treatment ISM001-055 safe, improves lung function, data show

Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a trial. The trial (NCT05938920) enrolled 71 patients with IPF across 21 sites in China who were randomly assigned to receive one of…

The big shift: My decision to stop working

I was recently asked when I stopped working and how I knew it was time. First, let me tell you: It wasn’t an easy decision. My idiopathic pulmonary fibrosis (IPF) diagnosis came on Jan. 31, 2017. At the time I was the senior vice president for a U.S.